Mindrank AI CEO on Business Strategy, AI Drug Discovery
THE SO WHAT
AI-first drug discovery is shifting from tooling to full-stack biotech businesses—who owns the IP, not just the models, is the real control point. If you’re in pharma or biotech BD, start mapping which AI shops have credible pipelines versus those selling services only.
READ THE SOURCE
MORE FROM THE WIRE
Deep & Emerging TechThe EPA’s Response to AI Data Center Backlash: Keep Building, but Keep It Hush-Hush
If the EPA removes the 30-day public comment period for many data center permits, AI infra buildout gets faster but also more politically fragile. Infra, cloud, and large AI buyers should treat community and regulatory risk as a first-class constraint, not something Washington quietly handles.
Deep & Emerging TechBrazil fines TikTok’s owner $29.9m over children’s data, including guest sessions
Brazil’s 153.7 million reais fine for mishandling children’s and guest-session data extends liability beyond logged-in users—“anonymous” modes are now clearly in scope. Any consumer app with minors in the funnel should re-audit consent, age gating, and guest telemetry before regulators do it for them.
Deep & Emerging TechIBM reveals plans for 'quantum fridges' — its next-gen cooling hardware, which could be the key to quantum computers finally reaching their potential
Quantum progress is now gated as much by cryogenic engineering as by qubit design—cooling two connected fridges to ~0.01 K is an infrastructure milestone, not a lab stunt. If you’re betting on quantum, start tracking who controls the full stack from dilution fridges to error correction, not just algorithm papers.
Deep & Emerging TechNorthrop CEO Expects ‘Decent Share’ of Golden Dome Contracts
A space-based defense program that could exceed $1T turns orbital infrastructure into a long-duration, government-backed demand engine. For dual-use and upstream suppliers — sensors, launch, comms, compute — this is a signal to map where your tech can plug into defense-grade space stacks.